Baudax Bio, Inc. (BXRX)

$0.8347

-0.01 (-1.22%)
Rating:
Recommendation:
-
Symbol BXRX
Price $0.8347
Beta 2.069
Volume Avg. 0.20M
Market Cap 5.361M
Shares () -
52 Week Range 0.67-27.055
1y Target Est -
DCF Unlevered BXRX DCF ->
DCF Levered BXRX LDCF ->
ROE 2687.14% Strong Buy
ROA -32.09% Strong Sell
Operating Margin -
Debt / Equity 401.01% Strong Buy
P/E -
P/B 0.35 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest BXRX news


Dr. Geraldine A. Henwood
Healthcare
Biotechnology
NASDAQ Capital Market

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.